AEON Biopharma reports Q2 2025 cash of $8.4M; advancing ABP-450 biosimilar milestones

AEON Biopharma, Inc.

2025-Q2 EPS reported $0.31

Cash and equivalents $8.4M as of June 30, 2025; expected to fund operations through Q4 2025 and Type 2a FDA meeting.
Primary structure and select functional analyses for ABP-450 expected to complete in Q3 2025.
Type 2a meeting with FDA on 351(k) biosimilar pathway anticipated in Q4 2025.
Pursuing ABP-450 as BOTOX biosimilar for all therapeutic indications; over $3B U.S. therapeutic market opportunity noted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.